Companies: 10,795·Total market cap: $144.5T
Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd.

GLMDNASDAQHealthcare● Active
$0.47
$-0.23(-32.57%)
Market Cap$2571403
P/E Ratio—
52W High$2.34
52W Low$0.411
Overview
Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

Galmed Pharmaceuticals Ltd. (GLMD) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · GLMD · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-2.33glmd eps ttm · glmd earnings per shareEarnings history
PE Ratio (TTM)—glmd pe ratio ttm · glmd price to earningsPE Ratio deep dive
Revenue (TTM)0.00glmd revenue ttm · glmd annual revenueFull revenue history
Dividend YieldNo Dividenddoes glmd pay dividends · glmd dividend yieldDividend history
Shares Outstanding4.3Mglmd shares outstanding · glmd floatShares outstanding history
Next EarningsJul 30, 2026Est.glmd earnings date · glmd next earningsEarnings history

Explore Galmed Pharmaceuticals Ltd. Data

glmd stock data · financials
Market Cap$2.6Mglmd market cap · glmd valuation
Analyst Forecast$— · Buy
DividendsNo Dividenddoes galmed pharmaceuticals ltd. pay dividends · glmd dividend yield
Revenue—galmed pharmaceuticals ltd. annual revenue · glmd revenue
EarningsEPS $-2.39+70.42%glmd earnings · glmd eps
PE Ratio—glmd pe ratio · glmd price to earnings

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
galmed pharmaceuticals ltd. revenue · glmd revenue 2025
FY 2025Net Income-$10.3M▼ 37.14% YoY
202320242025
galmed pharmaceuticals ltd. net income · glmd profit 2025
FY 2025EPS$-2.39▲ +70.42% YoY
202320242025
glmd eps · galmed pharmaceuticals ltd. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$10.3MEPS: $-2.33View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy16 analystsis glmd a buy · glmd analyst rating
Strong Buy
0
Buy
10
Hold
6
Sell
0
Strong Sell
0
12-Month Price Target
$—Low
$0.47Current
$—Avg Target
$—High
glmd price target · glmd 12 month forecast

Total: 16 · Buy rate: 62.5%

Stock Performance

Full History
1D-34.21%
1W-34.12%
1M-25.06%
3M-30.62%
YTD-38.99%
1Y-71.73%
5Y-99.93%

About Galmed Pharmaceuticals Ltd.

CEOAllen Baharaff
IPO DateMar 13, 2014
Employees3
CountryIL
Websitegalmedpharma.com

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for liver diseases. Its primary pipeline candidate is Aramchol, an orally administered drug cur…

BiotechnologyHealthcareNASDAQIL

what is galmed pharmaceuticals ltd. · glmd stock overview · galmed pharmaceuticals ltd. company profile · who is galmed pharmaceuticals ltd. ceo · glmd NASDAQ · galmed pharmaceuticals ltd. headquarters · galmed pharmaceuticals ltd. business segments

About Stock Overview & Key Data

Galmed Pharmaceuticals Ltd. (GLMD) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Mar 13, 2014. As of the latest trading session, GLMD stock price is $0.47, with a market capitalization of $2.6M. The stock has returned -71.73% over the past 12 months and -38.99% year-to-date.

According to 16 Wall Street analysts, the consensus rating for Galmed Pharmaceuticals Ltd. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Galmed Pharmaceuticals Ltd. reported revenue of — and net income of -$10.3M. For detailed data — including Galmed Pharmaceuticals Ltd. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Galmed Pharmaceuticals Ltd. (GLMD) stock price is $0.47. The stock is traded on NASDAQ under the ticker symbol GLMD. The 52-week range is $0.41 – $2.34.

GLMD stock priceGLMD quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice